MRNA cancer therapy takes on tough B-Cell tumors
NCT ID NCT07332663
First seen Jan 12, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This early-phase trial tests a new mRNA drug called WGb-0301 in 9 patients with B-cell cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. The drug uses lipid nanoparticles to deliver mRNA that targets a protein called CD19 on cancer cells. The main goal is to check safety and find the right dose, not yet to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
WGb-0301 injection (mRNA therapy targeting CD19, delivered via lipid nanoparticles)
What this could lead to
If it works, this could point toward a new treatment option for patients with B-cell cancers that have stopped responding to standard therapies.
What could go wrong
This is a very early, small trial (9 people) focused on safety, not effectiveness. The treatment may not work or could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.